CDKs as therapeutic targets for the human genetic disease tuberous sclerosis?

European Journal of Clinical Investigation

Volumn 39, Issue 12, 2009, Pages 1033-1035

  Rosner, M ^a   Dolznig, H ^a   Fuchs, C ^a   Siegel, N ^a   Valli, A ^a   Hengstschlager M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

MTOR; P27; Rapamycin; Tuberin; Tuberous sclerosis

Indexed keywords

CY 202; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLAVOPIRIDOL; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN P27; RAPAMYCIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TUBERIN; UNCLASSIFIED DRUG;

DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUBEROUS SCLEROSIS;

CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 70449476900     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02213.x     Document Type: Note

References (13)

1. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008 14 : 159 169.
2. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006 355 : 1345 1356.
3. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007 12 : 9 22.
4. Soucek T, Yeung RS, Hengstschläger M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 1998 95 : 15653 15658.
5. Rosner M, Hengstschläger M. Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem 2004 279 : 48707 48715.
6. Rosner M, Freilinger A, Hanneder M, Fujita N, Lubec G, Tsuruo T et al. p27 localization depends on the tumor suppressor protein tuberin. Hum Mol Genet 2007 16 : 1541 1556.
7. Rosner M, Freilinger A, Hengstschläger M. Akt regulates nuclear/cytoplasmic localization of tuberin. Oncogene 2007 26 : 521 531.
8. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 2008 30 : 701 711.
9. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phospohroylation and activation of serum- and glucocorticoid-induced protein kinase 1(SGK1). Biochem J 2008 416 : 375 385.
10. Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal 2009 21 : pe27.
11. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008 358 : 140 151.
12. Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL et al. Sirolimus therapy in tuberous sclerosis of sporadic lymphangioleiomyomatosis. N Engl J Med 2008 358 : 1963 1964.
13. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2007 29 : 16 21.